SKYRIZI
Google image searchProduct monograph
Active ingredient
risankizumab, 75 MG/0.83 ML
DIN: 02487454
Dosage form(s): SOLUTION
Route(s) of administration: SUBCUTANEOUS
Description: PREFILLED SYRINGE
Schedule: Prescription / Schedule D
Company: ABBVIE CORPORATION
Date: 13-MAY-2019
ATC:
- L04 — IMMUNOSUPPRESSANTS (ATC, ATC/DDD, )
- L04A — IMMUNOSUPPRESSANTS (ATC, ATC/DDD)
- L04AC — Interleukin inhibitors (ATC, ATC/DDD)
- L04AC18 — RIZANKIZUMAB (ATC/DDD)
